Geron Corporation Announces Proposed Public Offering of Common Stock

Geron's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version Menlo Park, Calif., January 29, 2014 - Geron Corporation (Nasdaq: GERN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Geron also expects to grant the underwriters an option to purchase up to an additional 15% of the shares of common stock offered in the public offering, exercisable for 30 days. All of the shares in the proposed offering are to be sold by Geron. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.BofA Merrill Lynch is acting as sole book-running manager; Stifel is acting as lead manager and Lazard Capital Markets LLC, Piper Jaffray & Co. and MLV & Co. LLC are acting as co-managers for the proposed offering.  This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. When available, copies of the preliminary prospectus supplement relating to the proposed offering may also be obtained from the offices of BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email at dg.prospectus_requests@baml.com.About GeronGeron is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.Forward-Looking Information is Subject to Risk and UncertaintyInvestors are cautioned that statements in this press release regarding the intention, completion, timing and option relating to the proposed public offering constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: whether or not Geron will be able to raise capital through the sale of shares of common stock; the final terms of the proposed offering, market and other conditions; whether there are any new significant adverse events reported relating to imetelstat; the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Geron will be able to complete the proposed public offering on acceptable terms, or at all. Geron will continue to need significant additional capital to fund its operations and may be unable to raise capital when needed, which would force Geron to delay, reduce or eliminate its imetelstat development program. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on other potential factors that could affect Geron's results and other risks and uncertainties can be found under the heading "Risk Factors" in Geron's periodic reports, including its quarterly report on Form 10-Q for the quarter ended September 30, 2013 and in the preliminary prospectus supplement related to the proposed offering to be filed with the Securities and Exchange Commission on or about the date hereof, each available on the SEC's web site at www.sec.gov. Geron expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.CONTACT:

News Source : Geron Corporation Announces Proposed Public Offering of Common Stock

Copy this html code to your website/blog to embed this press release.